Targeted intensification by a new preparative regimen for patients with low-grade B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan [ibritumomab tiuxetan Y-90] (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM [carmustine + etoposide + cytarabine + melphalan] followed by autologous stem cell transplantation (ASCT).
Latest Information Update: 31 Mar 2022
At a glance
- Drugs Cytarabine (Primary) ; Etoposide (Primary) ; Ibritumomab tiuxetan (Primary) ; Melphalan (Primary) ; Rituximab (Primary) ; Autologous stem cell therapy; Carmustine
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms Z-BEAM
- 26 Mar 2022 This trial has been completed in Belgium, according to European Clinical Trials Database record. (1 Mar 2009)
- 18 Jun 2012 Updated two-year overall survival data presented at the 17th Congress of the European Haematology Association, according to a Spectrum Pharmaceuticals media release.
- 07 Sep 2006 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.